These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16777679)

  • 21. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
    Zhou X; Smith QR; Liu X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases.
    Anthony DP; Hegde M; Shetty SS; Rafic T; Mutalik S; Rao BSS
    Life Sci; 2021 Jun; 274():119326. PubMed ID: 33711385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug delivery to the CNS and polymeric nanoparticulate carriers.
    Costantino L
    Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.
    Shahjin F; Chand S; Yelamanchili SV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):443-458. PubMed ID: 31485884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcellular brain drug delivery: A review on recent advancements.
    Azarmi M; Maleki H; Nikkam N; Malekinejad H
    Int J Pharm; 2020 Aug; 586():119582. PubMed ID: 32599130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neurological disorders and the blood-brain barrier. Strategies and limitations for drug delivery to the brain].
    Domínguez A; Álvarez A; Suárez-Merino B; Goñi-de-Cerio F
    Rev Neurol; 2014 Mar; 58(5):213-24. PubMed ID: 24570360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticles as novel carrier for brain delivery: a review.
    Agarwal A; Lariya N; Saraogi G; Dubey N; Agrawal H; Agrawal GP
    Curr Pharm Des; 2009; 15(8):917-25. PubMed ID: 19275654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug delivery to brain via the blood-brain barrier.
    Scherrmann JM
    Vascul Pharmacol; 2002 Jun; 38(6):349-54. PubMed ID: 12529929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis.
    Zheng Q; Chen ZX; Xu MB; Zhou XL; Huang YY; Zheng GQ; Wang Y
    Drug Deliv; 2018 Nov; 25(1):1617-1633. PubMed ID: 30334462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases.
    Mansor NI; Nordin N; Mohamed F; Ling KH; Rosli R; Hassan Z
    Curr Drug Deliv; 2019; 16(8):698-711. PubMed ID: 31456519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.
    Papisov MI; Belov VV; Gannon KS
    Mol Pharm; 2013 May; 10(5):1522-32. PubMed ID: 23316936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New experimental models of the blood-brain barrier for CNS drug discovery.
    Kaisar MA; Sajja RK; Prasad S; Abhyankar VV; Liles T; Cucullo L
    Expert Opin Drug Discov; 2017 Jan; 12(1):89-103. PubMed ID: 27782770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.
    Deo AK; Theil FP; Nicolas JM
    Mol Pharm; 2013 May; 10(5):1581-95. PubMed ID: 23256608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules.
    Crook ZR; Girard E; Sevilla GP; Merrill M; Friend D; Rupert PB; Pakiam F; Nguyen E; Yin C; Ruff RO; Hopping G; Strand AD; Finton KAK; Coxon M; Mhyre AJ; Strong RK; Olson JM
    J Mol Biol; 2020 Jun; 432(14):3989-4009. PubMed ID: 32304700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
    Crawford L; Rosch J; Putnam D
    J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.